Advisory Board

 

Caring4Cancer
Medical Advisory Board

 

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Dana-Farber Cancer Institute

James O. Armitage, MD
The Joe Shapiro Professor of Internal Medicine
Section of Oncology/Hematology
University of Nebraska Medical Center

Chandra P. Belani, MD
Deputy Director, Penn State Cancer Institute
Miriam Beckner Professor of Medicine
Penn State University School of Medicine

Howard A. Burris III, MD
Chief Medical Officer
Director of Drug Development
Sarah Cannon Research Institute
Tennessee Oncology

Jeremy R. Geffen, MD
President, Geffen Visions International
P4 Healthcare/Caring4Cancer

 

 

William J. Gradishar, MD
Professor of Medicine & Director of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine
Northwestern University

Hagop M. Kantarjian, MD
Chairman, Department of Leukemia
Professor of Medicine & Internist
MD Anderson Cancer Center
University of Texas

Maurie Markman, MD
Vice President, Clinical Research
MD Anderson Cancer Center
University of Texas

Robert J. Motzer, MD
Attending Physician
Memorial Sloan-Kettering Cancer Center

Daniel P. Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
Columbia University Medical Center

Latest Cancer News
Vaccine Against HPV-16 Effective for Vulvar Intraepithelial Neoplasia

November 6, 2009 — Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.

Small HER2-positive Breast Cancers Have a Higher Risk of Recurrence

November 6, 2009 — Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.

Alcohol May Reduce Risk of Thyroid Cancer

November 6, 2009 — Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.

Select news items provided by Reuters Health